Giving standard chemotherapy drugs in a specific sequence for some types of metastatic breast cancer can help reduce overall costs and improve the value of care while preserving quality of life, according to a study led by UNC Lineberger Comprehensive Cancer Center and UNC Gillings School of Global Public Health researchers.
FDA has issued a safety alert informing patients and providers about reports of squamous cell carcinoma and various lymphomas located in the capsule or scar tissue around breast implants. After an initial extensive review, we currently believe that the risk of SCC and other lymphomas occurring in the tissue around breast implants is rare.
Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard, along with clinicians at Washington University in St. Louis have identified biological markers in triple negative breast cancer that are associated with resistance to chemotherapy treatment.
FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer.
Lynparza (olaparib) was approved by the European Commission as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have HER2-negative, high-risk, early-stage breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
Jeffrey M. Rosen will receive the William L. McGuire Memorial Lecture Award at the 2022 San Antonio Breast Cancer Symposium, to be held Dec. 6-10, 2022.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Lynparza (olaparib) for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.
Photo credit: TANGRYSTAN, BrystkreftforeningenThe world’s first statue of a woman with incurable breast cancer—Cecilie, a 44-year-old mother of three—was unveiled at Eidsvoll Square, in front of Stortinget, the Norwegian Parliament, on June 20.
A multi-institutional study led by UNC Lineberger Comprehensive Cancer Center researchers found that diagnostic mammography results vary across racial and ethnic groups, with the rate of diagnostic accuracy highest in non-Hispanic white women and lowest in Hispanic women.
The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation.
